Nothing Special   »   [go: up one dir, main page]

HK1169326A1 - Inhibitors of influenza viruses replication - Google Patents

Inhibitors of influenza viruses replication

Info

Publication number
HK1169326A1
HK1169326A1 HK12110126.2A HK12110126A HK1169326A1 HK 1169326 A1 HK1169326 A1 HK 1169326A1 HK 12110126 A HK12110126 A HK 12110126A HK 1169326 A1 HK1169326 A1 HK 1169326A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
influenza viruses
viruses replication
replication
influenza
Prior art date
Application number
HK12110126.2A
Other languages
English (en)
Chinese (zh)
Inventor
.查理弗森
.克拉克
.本達拉格
.貝西埃爾
.庫特
鄧紅波
.德魯圖
.杜飛
.法莫
高淮
顧文鑫
.雅各布
.肯尼迪
.雷德波爾
.雷德福德
.馬爾泰斯
.佩洛拉
王天生
.瓦納馬科
.格曼
.瓊斯
姜敏
林超
周毅
.柏恩
.薩利圖羅
廣達儀
Original Assignee
沃泰克斯藥物股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42537408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1169326(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 沃泰克斯藥物股份有限公司 filed Critical 沃泰克斯藥物股份有限公司
Publication of HK1169326A1 publication Critical patent/HK1169326A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK12110126.2A 2009-06-17 2012-10-12 Inhibitors of influenza viruses replication HK1169326A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18771309P 2009-06-17 2009-06-17
US28778109P 2009-12-18 2009-12-18
PCT/US2010/038988 WO2010148197A1 (en) 2009-06-17 2010-06-17 Inhibitors of influenza viruses replication

Publications (1)

Publication Number Publication Date
HK1169326A1 true HK1169326A1 (en) 2013-01-25

Family

ID=42537408

Family Applications (4)

Application Number Title Priority Date Filing Date
HK12110126.2A HK1169326A1 (en) 2009-06-17 2012-10-12 Inhibitors of influenza viruses replication
HK16103636.6A HK1215675A1 (zh) 2009-06-17 2012-10-12 流感病毒複製抑制劑
HK15104769.4A HK1204322A1 (en) 2009-06-17 2012-10-12 Inhibitors of influenza viruses replication
HK16103417.1A HK1215530A1 (zh) 2009-06-17 2012-10-12 流感病毒複製抑制劑

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK16103636.6A HK1215675A1 (zh) 2009-06-17 2012-10-12 流感病毒複製抑制劑
HK15104769.4A HK1204322A1 (en) 2009-06-17 2012-10-12 Inhibitors of influenza viruses replication
HK16103417.1A HK1215530A1 (zh) 2009-06-17 2012-10-12 流感病毒複製抑制劑

Country Status (38)

Country Link
US (7) US20120171245A1 (sl)
EP (3) EP2442809B1 (sl)
JP (6) JP5721706B2 (sl)
KR (3) KR102050712B1 (sl)
CN (5) CN104151312B (sl)
AP (1) AP3631A (sl)
AR (1) AR077130A1 (sl)
AU (1) AU2010262905B2 (sl)
BR (1) BRPI1011993A2 (sl)
CA (1) CA2764177C (sl)
CL (1) CL2011003192A1 (sl)
CO (1) CO6491048A2 (sl)
CY (2) CY1118246T1 (sl)
DK (2) DK2442809T3 (sl)
EA (3) EA037529B1 (sl)
EC (1) ECSP12011610A (sl)
ES (2) ES2604667T3 (sl)
GE (3) GEP20156325B (sl)
HK (4) HK1169326A1 (sl)
HR (2) HRP20161577T1 (sl)
HU (1) HUE031048T2 (sl)
IL (2) IL216980B (sl)
LT (2) LT2442809T (sl)
ME (1) ME02558B (sl)
MX (2) MX2011013475A (sl)
NZ (2) NZ597059A (sl)
PE (2) PE20120508A1 (sl)
PH (1) PH12015501678B1 (sl)
PL (2) PL3141252T3 (sl)
PT (2) PT3141252T (sl)
RS (2) RS55341B1 (sl)
SG (3) SG10201405827PA (sl)
SI (2) SI3141252T1 (sl)
TR (1) TR201815272T4 (sl)
TW (4) TWI666209B (sl)
UY (1) UY32717A (sl)
WO (1) WO2010148197A1 (sl)
ZA (2) ZA201109127B (sl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2354140A1 (en) * 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
PH12015501678B1 (en) 2009-06-17 2022-07-06 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
RU2013132683A (ru) * 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
JP2013545817A (ja) * 2010-12-16 2013-12-26 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルス複製阻害物質
CA2822057A1 (en) * 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP5813223B2 (ja) 2011-07-04 2015-11-17 ロッタファーム バイオテック エス アール エル Ep4レセプターアンタゴニストとしての環状アミン誘導体
DK3141548T3 (da) 2011-07-05 2020-07-06 Vertex Pharma Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US10323012B2 (en) * 2012-06-05 2019-06-18 Hong Kong Baptist University Miliusanes as antiviral agents
WO2013184985A1 (en) * 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
KR102356487B1 (ko) 2012-11-21 2022-02-08 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 bmi-1 저해제
MX370588B (es) 2013-08-30 2019-12-16 Ptc Therapeutics Inc Inhibidores de la bmi-1 de pirimidina sustituida.
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
ES2843173T3 (es) * 2013-11-13 2021-07-16 Vertex Pharma Métodos para preparar inhibidores de la replicación de virus de la gripe
SG10201804026WA (en) * 2013-11-13 2018-06-28 Vertex Pharma Inhibitors of influenza viruses replication
CA2930105A1 (en) * 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Formulations of azaindole compounds
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
AU2015240535A1 (en) 2014-04-04 2016-10-20 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3177609A1 (en) * 2014-08-08 2017-06-14 Janssen Sciences Ireland UC Indoles for use in influenza virus infection
US9932346B2 (en) * 2014-09-08 2018-04-03 Janssen Sciences Ireland Uc Pyrrolopyrimidines for use in influenza virus infection
MA40773A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
MA40772A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
CN107207435B (zh) * 2015-01-16 2020-05-19 拜耳作物科学股份公司 制备4-氰基哌啶盐酸盐的方法
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2016191079A1 (en) * 2015-05-26 2016-12-01 Boropharm, Inc. Improved process for preparing boryl 7-azaindole compounds
AU2016359907B2 (en) 2015-11-27 2021-04-01 Janssen Sciences Ireland Uc Heterocyclic indoles for use in influenza virus infection
US10717732B2 (en) * 2015-12-09 2020-07-21 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2017118680A1 (en) * 2016-01-07 2017-07-13 Janssen Sciences Ireland Uc Functionalized pentanoic acids for use in influenza viral infections
AU2017209925B2 (en) * 2016-01-20 2021-04-08 Janssen Sciences Ireland Uc Aryl substituted pyrimidines for use in influenza virus infection
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017198122A1 (zh) * 2016-05-19 2017-11-23 四川大学 抗流感小分子化合物及其制备方法和用途
CN107759571B (zh) * 2016-08-16 2021-03-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
US10647693B2 (en) 2016-08-30 2020-05-12 North & South Brother Pharmacy Investment Company Limited Inhibitors of influenza virus replication, application methods and uses thereof
WO2018041263A1 (zh) 2016-09-05 2018-03-08 广东众生药业股份有限公司 抗流感病毒嘧啶衍生物
CN110088100B (zh) * 2016-11-08 2023-02-17 癌症研究科技有限公司 作为cdc7抑制剂的嘧啶酮衍生物
EP3555095B1 (en) * 2016-12-15 2023-04-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
HUE065438T2 (hu) * 2016-12-23 2024-05-28 Aquinnah Pharmaceuticals Inc Vegyületek, készítmények és alkalmazási eljárások
CN108276401B (zh) 2017-01-05 2020-12-22 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2018157830A1 (en) 2017-03-02 2018-09-07 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
EP3609502A1 (en) 2017-04-12 2020-02-19 Vertex Pharmaceuticals Incorporated Combination therapies for treating influenza virus infection
EA039181B1 (ru) * 2017-04-24 2021-12-15 Кокристал Фарма, Инк. Производные пирролопиримидина, пригодные в качестве ингибиторов репликации вируса гриппа
CN108727369B (zh) * 2017-04-25 2023-06-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN118239938A (zh) 2017-08-09 2024-06-25 戴纳立制药公司 化合物、组合物及方法
PT3676297T (pt) 2017-09-01 2023-08-29 Denali Therapeutics Inc Compostos, composições e métodos
CN109745309B (zh) * 2017-11-03 2022-01-28 香港浸会大学 作为抗病毒剂的密瘤杀
CN110117285B (zh) * 2018-02-07 2023-02-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
KR102484804B1 (ko) 2018-03-05 2023-01-04 광둥 레이노벤트 바이오테크 컴퍼니 리미티드 이미다졸계 화합물의 결정 형태, 염 형태 및 그의 제조 방법
JP2021520363A (ja) 2018-04-06 2021-08-19 ヤンセン ファーマシューティカルズ,インコーポレーテッド 結晶形態のピモジビル塩酸塩半水和物を調製するための等温反応性結晶化方法
CN110590768B (zh) * 2018-06-13 2021-02-26 银杏树药业(苏州)有限公司 杂环化合物、其组合物及其作为抗流感病毒药物的应用
KR20210038908A (ko) * 2018-07-27 2021-04-08 코크리스탈 파마, 아이엔씨. 인플루엔자바이러스 복제 억제제로서의 피롤로[2,3-b]피리딘 유도체
CA3109386A1 (en) 2018-08-17 2020-03-19 Ptc Therapeutics, Inc. Use of 5-fluoro-2-(6-fluoro-2-methyl-1h-benzo(d)imidazol-1-yl)-n4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine in the treatment of pancreatic cancer
MA54959A (fr) 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
CN113518618A (zh) 2019-02-13 2021-10-19 戴纳立制药公司 化合物、组合物及方法
WO2020181247A1 (en) * 2019-03-06 2020-09-10 Denali Therapeutics Inc. Compounds, compositions and methods
WO2020212399A1 (en) 2019-04-15 2020-10-22 Janssen Pharmaceutica Nv Method for preparing an alkyl trans-3-aminobicyclo[2.2.2]octane-2-carboxylic acid ester compound
US20200397784A1 (en) 2019-06-20 2020-12-24 Janssen Pharmaceuticals, Inc. Formulations of azaindole compounds
EP3992192A4 (en) * 2019-07-22 2022-08-17 Guangdong Raynovent Biotech Co., Ltd. Dominant salt forms of pyrimidine derivatives, and crystal forms thereof
EP4023647A4 (en) * 2019-08-30 2023-08-16 TSD Life Sciences Co., Ltd. IMIDAZOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE PRINCIPLE
CN114502150B (zh) * 2019-09-10 2023-03-24 广东众生睿创生物科技有限公司 一种用于治疗病毒性感冒的药物组合物及其制剂
RU2726119C1 (ru) * 2019-11-22 2020-07-09 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые производные полиолов, их применение, фармацевтическая композиция на их основе
CN117362318A (zh) 2020-07-10 2024-01-09 西藏海思科制药有限公司 Pb2抑制剂及其制备方法和用途
CN112979647B (zh) * 2021-03-12 2022-05-20 浙江大学 含氮杂氨基酸的氮杂吲哚衍生物及制备和应用

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349552A (en) 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
PT85662B (pt) 1986-09-10 1990-06-29 Sandoz Sa Processo para a preparacao de derivados de aza-indol e de indolizina e de composicoes farmaceuticas que os contem
MX19185A (es) 1989-01-20 1993-12-01 Pfizer Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
EP0763035A4 (en) 1994-06-09 1997-10-01 Smithkline Beecham Corp ENDOTHELIN RECEPTOR ANTAGONISTS
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
US6187713B1 (en) 1996-10-31 2001-02-13 Corning Incorporated Method of making activated carbon bodies having improved adsorption properties
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
WO2000040581A1 (en) 1999-01-07 2000-07-13 American Home Products Corporation 3,4-dihydro-2h-benzo[1,4]oxazine derivatives
CN1166636C (zh) 1999-01-07 2004-09-15 惠氏 用于治疗抑郁症的芳基哌嗪基-环己基吲哚衍生物
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
AR028475A1 (es) 1999-04-22 2003-05-14 Wyeth Corp Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
US20030153560A1 (en) 1999-04-23 2003-08-14 Salituro Francesco G. Inhibitors of c-Jun N-terminal kinases (JNK)
WO2001001986A1 (en) 1999-07-02 2001-01-11 Lipton Stuart A Method of reducing neuronal injury or apoptosis
GB9919843D0 (en) 1999-08-20 1999-10-27 Smithkline Beecham Plc Novel compounds
DE19948417A1 (de) 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
IL150420A0 (en) 1999-12-28 2002-12-01 Pharmacopeia Inc Pyrimidine and triazine kinase inhibitors
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
US7041277B2 (en) 2000-03-10 2006-05-09 Cadbury Adams Usa Llc Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
AU2001284823B2 (en) 2000-08-14 2006-11-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
EP1315741A2 (en) 2000-09-06 2003-06-04 Ortho-McNeil Pharmaceutical, Inc. A method for treating allergies
ES2309088T3 (es) 2000-09-06 2008-12-16 Ortho-Mcneil Pharmaceutical, Inc. Uso de pirazoles sustituidos para el tratamiento de alergias.
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
EP1322652A1 (en) 2000-09-22 2003-07-02 Eli Lilly And Company Stereoselective process for preparing cyclohexyl amine derivatives
PL363241A1 (en) 2000-12-22 2004-11-15 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
ES2360205T3 (es) 2001-03-02 2011-06-01 Agennix Ag Sistema de ensayo de tres híbridos.
ES2230484T3 (es) 2001-03-14 2005-05-01 Wyeth Derivados antidepresivos azaheterociclimeticos de 2,3-dihidro-1,4-dioxino (2,3-f) quinolina.
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US6559169B2 (en) 2001-04-24 2003-05-06 Wyeth Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-benzodioxan
US6656950B2 (en) 2001-04-25 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine
CN1267434C (zh) 2001-04-26 2006-08-02 惠氏公司 抗抑郁的(SSSRI)7,8-二氢-3H-6,9-二氧杂-1,3-二氮杂环戊二烯并[a]萘的氮杂环基甲基衍生物
WO2002088129A1 (en) 2001-04-26 2002-11-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline
WO2002088144A2 (en) 2001-04-26 2002-11-07 Wyeth ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-f]QUINOXALINE
US6593350B2 (en) 2001-04-26 2003-07-15 Wyeth Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole
CN1503798A (zh) 2001-04-26 2004-06-09 抗抑郁的氧杂环稠合的-[1,4]苯并二噁烷的氮杂环基甲基衍生物
PT1392700E (pt) 2001-04-30 2004-12-31 Wyeth Corp Derivados aza-heterociclilmetilo antidepressivos de 7,8-di-hidro-1,6,9-troxa-3-aza-ciclopenta(a)naftaleno
US6555560B2 (en) 2001-04-30 2003-04-29 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
BR0209901A (pt) 2001-05-17 2004-07-13 Wyeth Corp Processos para a sìntese de derivados de 2,3-dihidro-1,4-dioxino-[2,3-f] quinolina
ATE432929T1 (de) 2001-06-15 2009-06-15 Vertex Pharma 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US6903110B2 (en) 2001-07-25 2005-06-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
MXPA04001361A (es) 2001-08-14 2004-05-27 Toyama Chemical Co Ltd Metodo novedoso para inhibir el crecimiento de virus y/o metodo virucida, y un analogo novedoso de un nucleotido de pirazina o de un nucleosido de pirazina.
US20040236110A1 (en) 2001-09-26 2004-11-25 Ladouceur Gaetan H Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
US6667322B2 (en) 2001-10-05 2003-12-23 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
BR0308787A (pt) 2002-04-26 2005-01-11 Pfizer Prod Inc Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
AU2003237121A1 (en) 2002-04-26 2003-11-10 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
IL164209A0 (en) 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
ATE339419T1 (de) 2002-08-02 2006-10-15 Vertex Pharma Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
WO2004014912A1 (en) 2002-08-08 2004-02-19 Ribapharm Inc. Improved synthesis for hydroxyalkylated heterocyclic bases
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
PT1599478E (pt) 2003-02-26 2007-05-31 Boehringer Ingelheim Pharma Di-hidropteridinonas, proceso para a sua preparação e a sua utilização como medicamento
EP2295433A3 (en) 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
DE602004017654D1 (de) 2003-07-16 2008-12-18 Janssen Pharmaceutica Nv Triazolopyrimidin derivate als inhibitoren von glycogen synthase kinase-3
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
CA2540828A1 (en) 2003-09-30 2005-04-14 Scios Inc. Heterocyclic amides and sulfonamides
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
DK1696920T3 (en) 2003-12-19 2015-01-19 Plexxikon Inc RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
PT1730146E (pt) 2004-03-30 2011-07-11 Vertex Pharma Azaindoles úteis como inibidores de jak e outras proteínas quinases
US7514448B2 (en) 2004-04-02 2009-04-07 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
KR100476851B1 (ko) 2004-05-18 2005-03-17 (주)성신엔지니어링 중력식 섬유여과기
TW200616632A (en) 2004-06-17 2006-06-01 Plexxikon Inc Compounds modulating c-kit activity and uses therefor
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20060122213A1 (en) 2004-06-30 2006-06-08 Francoise Pierard Azaindoles useful as inhibitors of protein kinases
WO2006015123A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CN101068815B (zh) 2004-10-04 2012-09-05 千禧药品公司 有效作为蛋白激酶抑制剂的内酰胺化合物
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
EP1812440B1 (en) 2004-11-04 2010-09-22 Vertex Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
EP2316835A1 (en) 2004-11-22 2011-05-04 Vertex Pharmceuticals Incorporated Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
ZA200704902B (en) 2004-11-24 2008-10-29 Medpointe Healthcare Inc Compositions comprising azelastine and methods of use thereof
EP1828180A4 (en) 2004-12-08 2010-09-15 Glaxosmithkline Llc 1H-pyrrolo [2,3-BETA] PYRIDINE
MX2007007330A (es) 2004-12-16 2007-10-04 Vertex Pharma Piridonas de utilidad como inhibidores de quinasas .
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
KR20070104641A (ko) 2005-02-03 2007-10-26 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로 유용한 피롤로피리미딘
PL1896470T3 (pl) 2005-05-16 2011-03-31 Irm Llc Pochodne pirolopirydynowe jako inhibitory kinazy białkowej
EP2354140A1 (en) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
EP1931674B1 (en) 2005-09-30 2012-12-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
US20130096302A1 (en) 2005-11-22 2013-04-18 Hayley Binch Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
TWI405761B (zh) 2006-01-17 2013-08-21 Vertex Pharma 適合作為傑納斯激酶(janus kinase)抑制劑之氮雜吲哚
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
NZ570530A (en) 2006-02-14 2011-09-30 Vertex Pharma Pharmaceutical compositions comprising 6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4)diazepine derivatives
EP2004645A2 (en) 2006-02-14 2008-12-24 Vertex Pharmaceuticals, Inc. Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
DE102006012617A1 (de) 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
WO2007117494A1 (en) 2006-04-05 2007-10-18 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
US8252792B2 (en) * 2006-04-26 2012-08-28 F. Hoffman-La Roche Ag Pyrimidine derivatives as PI3K inhibitors
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
WO2007146057A2 (en) 2006-06-09 2007-12-21 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
US8778977B2 (en) 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
SI2050749T1 (sl) 2006-08-08 2018-04-30 Chugai Seiyaku Kabushiki Kaisha Derivat pirimidina kot pi3k inhibitor in njegova uporaba
JP5534811B2 (ja) * 2006-08-24 2014-07-02 アストラゼネカ アクチボラグ 増殖性疾患の治療に有用なモルホリノピリミジン誘導体
NZ577638A (en) 2006-12-14 2012-03-30 Vertex Pharma Tricyclic fused compounds useful as protein kinase inhibitors
US8247421B2 (en) 2006-12-21 2012-08-21 Vertex Pharmaceuticals Incorporated 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
CA2679701A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
JP5520057B2 (ja) 2007-03-09 2014-06-11 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリミジン
WO2008112651A2 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
PL2139892T3 (pl) 2007-03-22 2012-03-30 Takeda Pharmaceuticals Co Podstawione pirymidynodiazepiny użyteczne jako inhibitory plk1
CA2683453C (en) 2007-04-05 2013-06-11 Alla Chem, Llc Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-.beta.]indoles, methods for the production and use thereof
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием
MX2010001677A (es) 2007-08-15 2010-03-11 Vertex Pharma Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli
JP5410432B2 (ja) 2007-09-28 2014-02-05 サイクラセル リミテッド プロテインキナーゼ阻害剤としてのピリミジン誘導体
US9045248B2 (en) 2007-10-09 2015-06-02 European Molecular Biology Laboratory Soluble fragments of influenza virus PB2 protein capable of binding RNA-cap
EP2215089B1 (en) 2007-11-02 2012-06-27 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b]pyridine-4-yl]-phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
ES2381518T3 (es) 2007-11-05 2012-05-29 Novartis Ag Derivados del 4-bencilamino-1-carboxi acil-piperidina como inhibidores de CETP útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteroesclerosis
ATE522535T1 (de) 2008-02-25 2011-09-15 Hoffmann La Roche Pyrrolotriazin-kinasehemmer
EP2262498A2 (en) 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
US20110033473A1 (en) 2008-04-09 2011-02-10 Yoram Reiter Anti influenza antibodies and uses thereof
MX346186B (es) 2008-06-23 2017-03-10 Vertex Pharma Inhibidores de proteina cinasas.
AU2009271663B2 (en) 2008-06-23 2014-04-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010011756A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
CA2731496A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
JP5631310B2 (ja) 2008-07-23 2014-11-26 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 三環式ピラゾロピリジンキナーゼ阻害剤
WO2010129668A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
US20120093738A1 (en) 2009-06-11 2012-04-19 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
PH12015501678B1 (en) 2009-06-17 2022-07-06 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
CA2767089A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
RS54783B1 (sr) 2010-04-07 2016-10-31 Vertex Pharma Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline
PH12012502046A1 (en) 2010-04-14 2017-07-26 Array Biopharma Inc 5,7-substituted~imidazo[1,2-c]pyrimidines as inhibitors of jak kinases
EP2563125A4 (en) 2010-04-27 2013-10-02 Merck Sharp & Dohme AZAINDOLE AS JANUSKINASE HEMMER
JP2013545817A (ja) 2010-12-16 2013-12-26 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルス複製阻害物質
RU2013132683A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
CA2822057A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
DK3141548T3 (da) 2011-07-05 2020-07-06 Vertex Pharma Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2013070606A1 (en) 2011-11-07 2013-05-16 Vertex Pharmaceuticals Incorporated Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor
WO2013184985A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2014201332A1 (en) 2013-06-14 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical combinations useful for treating rheumatoid arthritis
CA2921198A1 (en) 2013-08-22 2015-02-26 Vertex Pharmaceuticals Incorporated Isotopically enriched azaindoles
MX2016003199A (es) 2013-09-12 2016-06-02 Alios Biopharma Inc Compuestos de azapiridona y usos de los mismos.
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
ES2843173T3 (es) 2013-11-13 2021-07-16 Vertex Pharma Métodos para preparar inhibidores de la replicación de virus de la gripe
CA2930105A1 (en) 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Formulations of azaindole compounds
SG10201804026WA (en) 2013-11-13 2018-06-28 Vertex Pharma Inhibitors of influenza viruses replication
EP3177609A1 (en) 2014-08-08 2017-06-14 Janssen Sciences Ireland UC Indoles for use in influenza virus infection
US9932346B2 (en) 2014-09-08 2018-04-03 Janssen Sciences Ireland Uc Pyrrolopyrimidines for use in influenza virus infection
MA40772A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
MA40773A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
AU2016359907B2 (en) 2015-11-27 2021-04-01 Janssen Sciences Ireland Uc Heterocyclic indoles for use in influenza virus infection
WO2017118680A1 (en) 2016-01-07 2017-07-13 Janssen Sciences Ireland Uc Functionalized pentanoic acids for use in influenza viral infections
AU2017209925B2 (en) 2016-01-20 2021-04-08 Janssen Sciences Ireland Uc Aryl substituted pyrimidines for use in influenza virus infection
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
EP3609502A1 (en) 2017-04-12 2020-02-19 Vertex Pharmaceuticals Incorporated Combination therapies for treating influenza virus infection

Also Published As

Publication number Publication date
AR077130A1 (es) 2011-08-03
KR101903354B1 (ko) 2018-10-04
AU2010262905A1 (en) 2012-01-12
RS55341B1 (sr) 2017-03-31
US20190151314A1 (en) 2019-05-23
EP2442809A1 (en) 2012-04-25
CN102458408A (zh) 2012-05-16
KR20170015551A (ko) 2017-02-08
ES2692396T3 (es) 2018-12-03
US20140142119A1 (en) 2014-05-22
JP2015034177A (ja) 2015-02-19
JP6620135B2 (ja) 2019-12-11
RS57869B1 (sr) 2018-12-31
SG10201405827PA (en) 2014-11-27
SI2442809T1 (sl) 2017-01-31
CN102458408B (zh) 2015-06-03
CN104151312B (zh) 2016-06-15
CN104922128A (zh) 2015-09-23
TWI574963B (zh) 2017-03-21
PE20160127A1 (es) 2016-02-24
ZA201500820B (en) 2016-05-25
DK2442809T3 (en) 2016-12-19
NZ597059A (en) 2014-01-31
AP3631A (en) 2016-03-08
CN104940202A (zh) 2015-09-30
EA201500266A1 (ru) 2015-10-30
US10874673B2 (en) 2020-12-29
US8829007B2 (en) 2014-09-09
KR102050712B1 (ko) 2019-12-02
US10039762B2 (en) 2018-08-07
HRP20181715T1 (hr) 2019-04-05
EA201500871A8 (ru) 2019-02-28
US20170100400A1 (en) 2017-04-13
US20140296201A1 (en) 2014-10-02
CY1118246T1 (el) 2017-06-28
JP2018002747A (ja) 2018-01-11
PT2442809T (pt) 2016-12-06
JP2012530713A (ja) 2012-12-06
AU2010262905B2 (en) 2015-04-16
JP2015038146A (ja) 2015-02-26
WO2010148197A1 (en) 2010-12-23
JP6030619B2 (ja) 2016-11-24
CA2764177A1 (en) 2010-12-23
PL3141252T3 (pl) 2019-01-31
TW201925196A (zh) 2019-07-01
IL216980A0 (en) 2012-02-29
IL262734A (en) 2018-12-31
ECSP12011610A (es) 2012-02-29
JP2020011990A (ja) 2020-01-23
HRP20161577T1 (hr) 2017-01-27
HK1215675A1 (zh) 2016-09-09
ME02558B (me) 2017-02-20
HUE031048T2 (en) 2017-06-28
US9518056B2 (en) 2016-12-13
CN104922128B (zh) 2019-12-20
PH12015501678A1 (en) 2020-06-22
CA2764177C (en) 2018-06-05
IL216980B (en) 2018-11-29
IL262734B (en) 2020-11-30
NZ619259A (en) 2015-07-31
UY32717A (es) 2011-01-31
CY1120778T1 (el) 2019-12-11
PE20120508A1 (es) 2012-05-09
SG10201405826RA (en) 2014-12-30
US9808459B2 (en) 2017-11-07
GEP20207129B (en) 2020-07-10
EP3141252B8 (en) 2019-03-13
TW201520211A (zh) 2015-06-01
TWI639596B (zh) 2018-11-01
KR101702609B1 (ko) 2017-02-03
KR20180108856A (ko) 2018-10-04
EA025276B1 (ru) 2016-12-30
KR20120097471A (ko) 2012-09-04
EA201500871A1 (ru) 2016-11-30
LT3141252T (lt) 2018-11-12
EA201270032A1 (ru) 2012-07-30
TW201103935A (en) 2011-02-01
PT3141252T (pt) 2018-11-14
EP3427738B1 (en) 2021-12-01
JP2016204390A (ja) 2016-12-08
PH12015501678B1 (en) 2022-07-06
US20120171245A1 (en) 2012-07-05
JP5721706B2 (ja) 2015-05-20
CO6491048A2 (es) 2012-07-31
EA030188B1 (ru) 2018-07-31
US9345708B2 (en) 2016-05-24
TW201728584A (zh) 2017-08-16
DK3141252T3 (en) 2018-11-19
SI3141252T1 (sl) 2018-12-31
TWI483941B (zh) 2015-05-11
US20180078553A1 (en) 2018-03-22
CN110540538A (zh) 2019-12-06
PL2442809T3 (pl) 2017-02-28
TR201815272T4 (tr) 2018-11-21
AP2012006067A0 (en) 2012-02-29
MX348066B (es) 2017-05-26
EP3141252A1 (en) 2017-03-15
BRPI1011993A2 (pt) 2021-07-06
GEP20156325B (en) 2015-07-10
ES2604667T3 (es) 2017-03-08
JP6348939B2 (ja) 2018-06-27
LT2442809T (lt) 2016-12-12
ZA201109127B (en) 2015-07-29
US20160152614A1 (en) 2016-06-02
TWI666209B (zh) 2019-07-21
EP3141252B1 (en) 2018-07-25
EP3427738A1 (en) 2019-01-16
CN104151312A (zh) 2014-11-19
EP2442809B1 (en) 2016-08-31
HK1204322A1 (en) 2015-11-13
GEP20227397B (en) 2022-07-25
CL2011003192A1 (es) 2013-01-04
EA037529B1 (ru) 2021-04-08
CN104940202B (zh) 2018-10-16
MX2011013475A (es) 2012-03-14
HK1215530A1 (zh) 2016-09-02
SG176722A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
HRP20181715T1 (hr) Inhibitori replikacije virusa gripe
AP3867A (en) Inhibitors of influenza viruses replication
HUS1700002I1 (hu) Hepatitis C vírus replikációjának inhibitorai
HK1178165A1 (en) Novel inhibitors of hepatitis virus replication
GB0908394D0 (en) Novel viral replication inhibitors
IL214606A0 (en) Inhibitors of hiv replication
GB0913425D0 (en) Novel inhibitors of viral replication

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: ADDITION OF INVENTOR: FRANCESCO G. SALITURO F

Effective date: 20160321

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220622